Coprococcus eutaxus strain and application thereof

Abstract

The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.

Description

Technical Field

[0001] The present invention relates to the technical field of probiotics, and specifically to a Coprococcus eutactus strain and its application. Background Art

[0002] Metabolic associated fatty liver disease (MAFLD) is part of the metabolic syndrome and is often accompanied by type 2 diabetes mellitus (T2DM), insulin resistance, and obesity, imposing a great burden on society. The gut microbiota plays a key role in MAFLD, especially in the progression to more advanced disease stages.

[0003] Coprococcus is considered to have important metabolic functions in the gut, especially the production of short-chain fatty acids (SCFAs), such as butyrate. Butyrate is crucial for the health of intestinal epithelial cells and has anti-inflammatory and gut barrier function-maintaining effects. The abundance of Coprococcus is associated with metabolic diseases such as obesity and type 2 diabetes. Research shows that Coprococcus may affect the metabolic health of the host by regulating the gut microbiota structure and metabolites. However, the therapeutic effect and mechanism of action of Coprococcus eutactus on MAFLD have not been elucidated. Therefore, we propose a Coprococcus eutactus strain and its application to solve the problems raised above.

[0004] The above information disclosed in this background art is only used to increase the understanding of the background art of the present invention. Therefore, it may include prior art that is not known to those of ordinary skill in the art. Summary of the Invention

[0005] The purpose of the present invention is to provide a Coprococcus eutactus strain and its application to solve the problems raised in the above background art.

[0006] To achieve the above purpose, the present invention provides the following technical solution: A Coprococcus eutactus strain named Coprococcus eutactus GZSY125, with a deposit number of CGMCC No. 66029, a deposit date of March 18, 2025, a deposit classification named Coprococcus eutactus, and a deposit unit of the Guangdong Provincial Culture Collection of Microorganisms, with the address of the deposit unit being the 5th floor of Building 59, No. 100 Dashanyuan, Xianlie Middle Road, Guangdong Province.

[0007] Preferably, the sequence of the 16s rDNA of the Coprococcus eutactus strain is as shown in SEQ ID NO: 1.

[0008] The present invention also provides the use of the above-mentioned Coprococcus eutactus GZSY125 in the preparation of a probiotic preparation for improving metabolic associated fatty liver disease.

[0009] Preferably, the metabolic associated fatty liver disease includes metabolic associated fatty liver disease caused by applying a high-fat, high-sugar and high-cholesterol diet to type 2 diabetes samples.

[0010] Preferably, the probiotic preparation is a drug or a food.

[0011] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0012] The present invention provides a Coprococcus eutactus, which can significantly improve liver lipid accumulation, inflammation and fibrosis, and has a certain therapeutic effect on metabolic associated fatty liver disease (MAFLD), providing a new treatment idea for clinically intervening in MAFLD and having important clinical significance for the treatment of MAFLD.

[0013] The above summary is only for the purpose of the specification and is not intended to be limiting in any way. In addition to the above-described illustrative aspects, embodiments and features, further aspects, embodiments and features of the present invention will be readily apparent by reference to the drawings and the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 : Colony state diagram of Coprococcus eutactus GZSY125 growing on Columbia blood agar plate;

[0015] Figure 2 : Schematic diagram of the position of Coprococcus eutactus GZSY125 in the phylogenetic tree;

[0016] Figure 3 : Liver pathology, body weight, liver weight and serum biochemical index conditions of each group of db / db mice:

[0017] A: Hematoxylin-eosin staining (H&E staining) and Oil Red O staining of mouse liver tissue;

[0018] B: Body weight, liver weight and liver index (liver weight / body weight) of mice;

[0019] C: Levels of alanine aminotransferase (ALT), cholesterol (CHO), and low-density lipoprotein (LDL) in mouse serum;

[0020] Compared with the control group, *P < 0.05, **P < 0.01;

[0021] Figure 4 : Expression of genes partially related to liver lipid, inflammation, and fibrosis metabolism in db / db mice;

[0022] A: Relative mRNA expression levels of genes related to lipid, inflammation, and fibrosis metabolism in mouse liver;

[0023] B: Protein expression of FASN and Fabp5 in mouse liver;

[0024] C: Distribution of TGF-β1 and CCL3 in mouse liver;

[0025] Compared with the control group, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001;

[0026] Figure 5 : Liver pathology, liver weight, and serum biochemical indexes of each group of MCD mice;

[0027] A: Hematoxylin-eosin staining (H&E staining), Oil Red O staining, and Masson staining of mouse liver tissue;

[0028] B: Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), cholesterol (CHO), and low-density lipoprotein (LDL) in mouse serum;

[0029] C: Liver weight and liver index (liver weight / body weight) of mice;

[0030] *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001;

[0031] Figure 6 : Relative mRNA expression levels of genes related to lipid, inflammation, and fibrosis metabolism in the liver of MCD mice; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Specific implementation manners

[0032] Next, the technical solutions in the embodiments of the present invention will be clearly and completely described in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0033] The present invention provides a Coprococcus eutactus strain, named Coprococcus eutactus GZSY125, which is isolated from the feces of a healthy donor.

[0034] The present invention also provides the use of Coprococcus eutactus GZSY125 in the preparation of a probiotic preparation for improving metabolic associated fatty liver disease.

[0035] The therapeutic effect and potential mechanism of Coprococcus eutactus GZSY125 strain on a mouse model of metabolic associated fatty liver disease (MAFLD) are further verified through the following experiments and results.

[0036] 1. Experiment

[0037] 1.1 Grouping and treatment of experimental animals

[0038] Ten 6-week-old male spontaneous diabetic db / db mice were randomly divided into 2 groups, with 5 mice in each group. The control group of mice was fed with SPF-grade maintenance feed for 4 weeks, and the treatment group of mice was further given Coprococcus eutactus GZSY125 (10 9 CFU / mouse / day) for 4 weeks. The control group of mice was simultaneously gavaged with the same volume of PBS buffer.

[0039] Another 15 8-week-old male C57BL / 6J mice were randomly divided into 3 groups, with 5 mice in each group. The control group of mice was fed with MCS feed for 6 weeks, the model group of mice was fed with methionine choline-deficient MCD feed (60% fat, 0.1% methionine, no choline added) for 6 weeks, and the treatment group of mice was given Coprococcus eutactus GZSY125 (10 9 CFU / mouse / day) by gavage for 4 weeks after feeding with MCD feed for 2 weeks. The control group and the model group of mice were simultaneously gavaged with the same volume of PBS buffer.

[0040] During the experiment, body weight was monitored every two days. After the experiment ended, liver tissues were collected, gross morphological photos were taken, and liver weight was recorded. The liver index was calculated as liver weight / body weight * 100%; serum samples were collected to monitor the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), cholesterol (CHO), and low-density lipoprotein (LDL).

[0041] 1.2 Detection of serum biochemical indicators

[0042] After the mouse blood specimens were allowed to stand for 1 h, they were centrifuged at 3000 rpm for 15 min. The upper-layer serum was taken, and the contents of ALT, AST, TG, CHO, and LDL in the serum were measured using relevant assay kits on a Mindray BS-480 automatic biochemical analyzer.

[0043] 1.3 Hematoxylin-eosin (H&E) staining, Masson staining, and Oil Red O staining

[0044] Part of the mouse liver lobe was placed in 4% paraformaldehyde for fixation for 24 h, then embedded in paraffin and sectioned. Hematoxylin-eosin (H&E) staining and Masson staining were performed, and finally dehydrated and sealed. Microscopic images were collected and analyzed; another part of the liver lobe was fixed in 4% paraformaldehyde for 24 h, then embedded in OCT embedding medium and cryosectioned. Oil Red O staining was performed, and finally sealed. Microscopic images were collected and analyzed.

[0045] 1.4 Quantitative real-time polymerase chain reaction (qPCR)

[0046] Total RNA was extracted from mouse liver using a high-purity RNA extraction kit (ER501-01-V2, TransGen Biotech Co., Ltd., Beijing), and the total RNA was reverse-transcribed into cDNA using Prime Script RT reagent Kit with gDNA Eraser (RR047A, Takara). TB Premix Ex Taq TMII. Real-time fluorescence quantitative PCR (qPCR) was performed using the FAST qPCR (RR820A, Takara). After amplification, the CT value was obtained. Using GAPDH as an internal reference, the relative expression levels of each target gene were calculated by the 2-ΔΔCT method. All primers used were synthesized by Shanghai Sangon Biotech Co., Ltd. The following are the specific primer sequences:

[0047] For GAPDH, the forward primer is 5’-ACATCATCCCTGCATCCACT-3’, and the reverse primer is 5’-GTCCTCAGTGTAGCCCAAG-3’;

[0048] For CD36, the forward primer is 5’-ATGGGCTGTGATCGGAACTG-3’, and the reverse primer is 5’-GTCTTCCCAATAAGCATGTCTCC-3’;

[0049] For FASN, the forward primer is 5’-CACAGTGCTCAAAGGACATGCC-3’, and the reverse primer is 5’-CACCAGGTGTAGTGCCTTCCTC-3’;

[0050] For ACC1, the forward primer is 5’-GTTCTGTTGGACAACGCCTTCAC-3’, and the reverse primer is 5’-GGAGTCACAGAAGCAGCCCATT-3’;

[0051] For CPT1c, the forward primer is 5’-TCTTCACTGAGTTCCGATGGG-3’, and the reverse primer is 5’-ACGCCAGAGATGCCTTTTCC-3’;

[0052] For Fabp5, the forward primer is 5’-TGAAAGAGCTAGGAGTAGGACTG-3’, and the reverse primer is 5’-CTCTCGGTTTTGACCGTGATG-3’;

[0053] For TNFα, the forward primer is 5’-GGTGCCTATGTCTCAGCCTCTT-3’, and the reverse primer is 5’-GCCATAGAACTGATGAGAGGGAG-3’;

[0054] For IL-1α, the forward primer is 5’-CGAAGACTACAGTTCTGCCATT-3’, and the reverse primer is 5’-GACGTTTCAGAGGTTCTCAGAG-3’;

[0055] IL-6, forward primer 5’-TACCACTTCACAAGTCGGAGGC-3’, reverse primer 5’-CTGCAAGTGCATCATCGTTGTTC-3’;

[0056] IL-1β, forward primer 5’-TGGACCTTCCAGGATGAGGACA-3’, reverse primer 5’-GTTCATCTCGGAGCCTGTAGTG-3’;

[0057] CCL3, forward primer 5’-TTCTCTGTACCATGACACTCTGC-3’, reverse primer 5’-CGTGGAATCTTCCGGCTGTAG-3’;

[0058] Col1a1, forward primer 5’-GCTCCTCTTAGGGGCCACT-3’, reverse primer 5’-CCACGTCTCACCATTGGGG-3’;

[0059] TGF-β1, forward primer 5’-CTCCCGTGGCTTCTAGTGC-3’, reverse primer 5’-GCCTTAGTTTGGACAGGATCTG-3’.

[0060] 1.5 Western blot analysis

[0061] Take 50 mg of liver tissue and lyse it thoroughly with 700 μL of RIPA lysis buffer. Centrifuge at 14000 rpm for 10 min and take the supernatant. Determine the protein concentration by the BCA method. Prepare and use a 10% polyacrylamide gel, load 50 μg per well, perform electrophoresis and membrane transfer. After blocking with 5% non-fat milk for 1 h, incubate with the primary antibody (antibody concentration 1:1000) at 4°C for 16 h, and finally incubate with the secondary antibody for 1 h and develop the image.

[0062] 1.6 Immunofluorescence (IF)

[0063] Take a part of the mouse liver lobe, fix it in 4% paraformaldehyde for 24 h, embed it in paraffin and section it. After baking the section at 65°C for 1 h, dewax it with 100%, 90%, 80%, and 70% ethanol respectively. Prepare citrate buffer (PH = 6.0) for antigen retrieval and block peroxidase with 3% hydrogen peroxide. After sealing the section, incubate with the primary antibody at 4°C for 16 h. After rewarming, add the fluorescent secondary antibody containing DPAI, incubate at room temperature in the dark for 30 min, and finally observe and scan the image using a microscope.

[0064] 1.7 Bacterial strains and culture

[0065] The Coprococcus eutactus GZSY125 used was isolated from healthy donors.

[0066] Coprococcus eutactus GZSY125 was cultured in an anaerobic environment (80% N2, 10% H2, 10% CO2) at 37 °C. The solid medium used was Columbia blood agar plate (CP0160, Guangdong Huankai Microbial Science and Technology Co., Ltd.). The bacterial solution was gently shaken and mixed evenly. After centrifugation at 3000 rpm for 10 min, the supernatant was discarded, and 1 mL of PBS buffer was added to resuspend it, which was then used for gavage of the mice in the treatment group.

[0067] 1.816 sRNA gene sequencing results (SEQ ID NO: 1)

[0068] >GZSY125 Coprococcus eutactus

[0069]

[0070] 1.9 Statistical analysis

[0071] Data were analyzed using Graphpad Prism 9.0 software (LaJolla, CA) and SPSS 21.0. Independent sample unpaired t-tests were used for pairwise comparisons of measurement data that conform to a normal distribution. P < 0.05 indicates that the difference is statistically significant.

[0072] 2. Results

[0073] 2.1 Growth characteristics and phylogenetic relationship of Coprococcus eutactus GZSY125

[0074] Coprococcus eutactus belongs to the family Lachnospiraceae, the genus Coprococcus, is a Gram-positive bacterium, strictly anaerobic, with an optimal growth temperature of 37 °C, and produces small white colonies on blood agar plates. It can utilize fermentable carbohydrates such as glucose, fructose, and lactose to produce short-chain fatty acids (SCFAs) such as butyric acid, acetic acid, and propionic acid (as Figure 1 shown).

[0075] The phylogenetic tree shows the classification of different Coprococcus species and their related strains (as Figure 2 shown)), and different Coprococcus species are shown in the tree (e.g., Coprococcus eutactus, Coprococcus hominis, Coprococcus comes, Coprococcus ammoniilyticus, Coprococcus callus) and multiple strains of them. Coprococcus eutactus contains 5 strains, and the bootstrap value of this branch is 100, indicating that the gene sequences among Coprococcus eutactus strains are highly similar and the phylogenetic relationship is relatively close.

[0076] 2.2 Coprococcus eutactus GZSY125 alleviates MAFLD liver injury and lipid accumulation in db / db mice

[0077] At the end of the experiment, the mice were dissected. The dissection data of the mice showed that compared with the control group mice, the liver color of the treatment group mice was dark red in the healthy state, the liver lobes were clearly divided, and the liver volume was reduced. To explore the effect of Coprococcus eutactus GZSY125 on liver fat deposition in MAFLD mice, pathological sections of the liver tissues of each group of mice were stained with H&E and oil red. The H&E staining of the liver tissues showed that fatty degeneration occurred in the liver tissues of the control group mice, mainly manifested as swelling of the liver tissue cells, the appearance of vacuoles of different sizes in the cytoplasm, and the nucleus was squeezed to one side; the oil red O staining also showed that more obvious lipid droplets appeared in the liver tissues of the control group mice. Observing the treatment group, the number of vacuoles decreased, and the clear hepatic lobule structure was visible( Figure 3 -A). All the above data indicate that Coprococcus eutactus GZSY125 can reduce liver fatty degeneration in NAFLD model mice, suggesting that Coprococcus eutactus GZSY125 has a good protective effect on liver fatty degeneration.

[0078] The initial body weight of the treatment group mice of the same week age was lighter than that of the control group mice; compared with the control group, the body weight of the treatment group mice was significantly lower than that of the control group. Under the same feeding conditions, starting from the 12th day of feeding, the weight difference between the two groups was obvious. The body weight of the treatment group mice was always lower than that of the control group mice, and the liver weight or liver weight / body weight of the treatment group mice was significantly lower than that of the control group( Figure 3 -B).

[0079] Serum ALT, CHO, and LDL were used to evaluate liver injury and lipid accumulation. To explore whether Coprococcus eutactus GZSY125 can relieve or inhibit liver injury and lipid accumulation in MAFLD mice, the changes in the levels of ALT, CHO, and LDL in the sera of each group of mice were detected. As Figure 3 shown in -C, in both the control group and the treatment group, the levels of serum ALT, CHO, and LDL in the treatment group mice were significantly decreased, suggesting that Coprococcus eutactus GZSY125 can relieve liver injury and lipid accumulation in MAFLD mice.

[0080] 2.3 Coprococcus eutactus GZSY125 inhibits the expression of genes related to inflammation, lipid metabolism, and fibrosis in MAFLD of db / db mice

[0081] To further investigate the mechanism by which Coprococcus eutactus GZSY125 alleviates or treats MAFLD, the mRNA expression levels of inflammation-related genes (TNF-α, IL-1α, IL-6, IL-1β, CCL3), lipid metabolism (CD36, FASN, ACC1, CPT1c, Fabp5), and fibrosis (Col1a1, TGF-β1) were detected by qPCR respectively. Statistical analysis by qPCR showed that compared with the control group, all three indicators decreased in the treatment group, among which CPT1c (P<0.001), IL-6 (P<0.001), IL-1α (P<0.0001), and Col1a1 (P<0.0001) decreased significantly. In addition, immunoblotting and immunofluorescence showed that the protein expression levels of FASN, Fabp5, TGF-β1, and CCL3 were lower in the treatment group than in the control group. The above data indicate that Coprococcus eutactus GZSY125 plays an anti-inflammatory role, reduces lipid accumulation, and has an anti-fibrotic effect in MAFLD.

[0082] 2.4 Coprococcus eutactus GZSY125 alleviates liver inflammation and fibrosis in MAFLD of MCD mice

[0083] To explore whether Coprococcus eutactus GZSY125 can alleviate or inhibit liver injury and lipid accumulation in MAFLD mice, the changes in the levels of ALT, AST, TG, CHO, and LDL in the sera of mice in each group fed with MCD diet were detected. As shown in Figure 5 -B, in both the control group and the treatment group, the levels of serum AST and CHO in the treatment group mice decreased significantly (P<0.001), suggesting that Coprococcus eutactus GZSY125 can alleviate liver injury and lipid accumulation in MAFLD mice. The body weight and liver weight / body weight of the control group mice were always lower than those of the model group and the treatment group mice, but the body weight of the treatment group mice was still lower than that of the model group (P<0.001). At the same time, the body weight and liver weight of mice in each group were detected, and it was found that the body weight and liver weight / body weight of the control group mice were always lower than those of the model group and the treatment group mice, but the body weight of the treatment group mice was still lower than that of the model group (P<0.001).

[0084] In addition, the liver pathology of the MCD mouse model was observed. The control group (fed with MCS diet) had regular liver lobules, central veins, etc., while the model group (fed with high-fat diet) showed obvious fatty degeneration of hepatocytes, manifested as cell swelling, uneven vacuolar lipid droplets, and the nucleus was pushed to one side. In the treatment group, oil red O staining showed a reduction in liver lipid droplets. Moreover, compared with the control group, the inflammation in the liver lobules of the treatment group decreased, and the degree of fibrosis was significantly reduced ( Figure 5 -A).

[0085] 2.5 Coprococcus eutactus GZSY125 Inhibits the Expression of Inflammatory, Lipid Metabolism, and Fibrosis-Related Genes in MAFLD of MCD Mice

[0086] To explore the mechanism by which Coprococcus eutactus GZSY125 alleviates or treats MAFLD in MCD mice, the transcriptional mRNA expression levels of inflammation-related genes (TNF-α, IL-6, CCL3), lipid metabolism (CD36, FASN, CPT1c, FABP5), and fibrosis (Col1a1, TGF-β1) genes were detected by qPCR. Statistical analysis of qPCR showed that compared with the model group, all three indicators decreased in the treatment group, among which Fabp5 (P<0.001), TGF-β1, and CCL3 (P<0.0001) decreased significantly. The above data indicate that Coprococcus eutactus GZSY125 plays an anti-inflammatory, lipid-accumulation-reducing, and anti-fibrotic role in the MAFLD of MCD mouse models.

[0087] Conclusion: Two MAFLD mouse models were constructed in the experiments of this invention. db / db mice had obvious MAFLD symptoms such as significant liver lipid accumulation and hepatocyte steatosis. After being fed with SPF-grade maintenance feed for 4 weeks and the mice in the treatment group were given intragastric administration of Coprococcus eutactus GZSY125, compared with the control group mice, the body weight growth trend slowed down significantly, the liver weight decreased significantly, and significant improvements were observed in serum biochemical indexes, liver pathology, etc.( Figure 3 ) However, liver fibrosis rarely occurred in db / db mice. Therefore, a mouse model induced by MCD diet was also used. C57BL / 6J mice fed with MCD feed for 6 weeks could develop liver inflammation after 2 weeks and liver fibrosis after 6 weeks, with significant increases in serum AST and ALT levels. At the same time, lobular inflammation of hepatocytes could also be observed. After the mice in the treatment group were given 10 9 CFU / mouse / day Coprococcus eutactus GZSY125 for treatment for 4 weeks, compared with the model group fed with MCD feed alone, the levels of serum ALT, AST, TG, CHO, and LDL decreased significantly, and liver inflammation and fibrosis were significantly improved( Figure 5 ).

[0088] Elevated serum TG and LDL levels are important factors promoting the progression of MAFLD. Among them, an important component of LDL, such as low-density lipoprotein cholesterol (LDL-c), is one of the risk factors for MAFLD. Compared with the control group or the model group of mice, the serum TG and LDL levels of the treatment group of mice were significantly decreased ( Figure 3 , Figure 5 ). Fatty acid synthase (FASN) is a key enzyme in fatty acid metabolism. The dysregulation of FASN can lead to lipid accumulation in the body. Fatty acid-binding protein 5 (FABP5) is a driver of obesity and MAFLD-induced hepatocellular carcinoma, which can alter cellular fatty acid distribution and metabolism. Evidence shows that both qPCR and Western blot showed a decrease in the transcriptional and expression levels of FASN and Fabp5 genes ( Figure 4 , Figure 6 ). It is proved that Coprococcus eutactus GZSY125 can reverse the hepatic lipid deposition caused by MAFLD to a certain extent.

[0089] The levels of pro-inflammatory cytokines in adipose tissue are significantly higher in obese people. The increase in the concentrations of pro-inflammatory cytokines, including IL-1β, IL-6, and TNFα, is common in the adipose tissue of obese individuals. TNF-α is a type II transmembrane protein responsible for signal transduction leading to carcinogenesis and immune responses. It is a well-studied pro-inflammatory cytokine mainly produced by activated macrophages. Transforming growth factor-beta 1 (TGF-β1) is a well-known fibrocyte factor. When injury occurs, the secretion of TGF-β1 increases in the fibrotic microenvironment. We detected the mRNA levels of some genes related to inflammation and fibrosis and found that the relative mRNA levels of IL-1β, IL-6, TNFα, and TGF-β1 in the treatment group of mice were significantly decreased compared with those in the control group or the model group of mice ( Figure 4 , Figure 6 ). The immunofluorescence results also showed a significant decrease in the expression of TGF-β1 in the liver of the treatment group of mice ( Figure 4 ). These results prove that Coprococcus eutactus GZSY125 can improve the hepatic inflammation and fibrosis of MAFLD.

[0090] Although the embodiments of the present invention have been shown and described above, it can be understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those of ordinary skill in the art can make changes, modifications, substitutions, and variations to the above embodiments within the scope of the present invention.

Claims

1. A Coprococcus eutactus strain, characterized in that: The Coprococcus eutactus strain is named Coprococcus eutactus GZSY125, with the deposit number CGMCC No. 66029, the deposit date being March 18, 2025, the deposit classification named Coprococcus eutactus, the deposit unit being the Guangdong Provincial Culture Collection Center of Microorganisms, and the address of the deposit unit being the 5th floor, Building 59, No. 100 Compound, Xianlie Middle Road, Guangdong Province.

2. The Coprococcus eutactus strain according to claim 1, characterized in that: The sequence of the 16s rDNA of the Coprococcuseutactus strain is as shown in SEQ ID NO:

1.

3. Use of Coprococcus eutactus GZSY125 according to claim 1 in the preparation of a probiotic preparation for improving metabolic associated fatty liver disease.

4. The application according to claim 3, characterized in that: The metabolic associated fatty liver disease includes metabolic associated fatty liver disease caused by applying high-fat, high-sugar and high-cholesterol to type 2 diabetes samples.

5. The application according to claim 3, characterized in that: The probiotic preparation is a drug or food.

Images